Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASRT Assertio	$0.81 -0.6%	$0.69	$0.51 ▼ $1.38	$78.25M	0.28	293,568 shs	117,616 shs
CABA Cabaletta Bio	$1.71 +3.6%	$1.67	$0.99 ▼ $6.26	$156.41M	2.74	1.33 million shs	1.25 million shs
EQ Equillium	$1.14 +16.3%	$0.45	$0.27 ▼ $1.50	$40.72M	1.15	21.52 million shs	5.55 million shs
INMB INmune Bio	$2.53 +3.3%	$3.89	$1.89 ▼ $11.64	$67.26M	0.97	2.97 million shs	527,682 shs

7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASRT Assertio	0.00%	+11.54%	+21.36%	+22.12%	-24.01%
CABA Cabaletta Bio	0.00%	+25.74%	+1.79%	-15.76%	-60.96%
EQ Equillium	0.00%	+130.21%	+170.78%	+204.81%	+42.68%
INMB INmune Bio	0.00%	-1.17%	+12.95%	-67.81%	-62.41%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ASRT Assertio	2.5039 of 5 stars	3.5	2.0	2.1	0.8	1.3
CABA Cabaletta Bio	2.7148 of 5 stars	3.5	4.0	2.1	0.8	0.6
EQ Equillium	2.8183 of 5 stars	3.2	5.0	2.9	1.7	0.0
INMB INmune Bio	1.9951 of 5 stars	3.3	2.0	1.4	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASRT Assertio	3.00	Buy	$2.38	192.09% Upside
CABA Cabaletta Bio	3.00	Buy	$14.43	743.78% Upside
EQ Equillium	2.33	Hold	$3.00	163.16% Upside
INMB INmune Bio	2.57	Moderate Buy	$18.40	627.27% Upside

Current Analyst Ratings Breakdown

Latest EQ, ASRT, CABA, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/12/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$3.50 ➝ $3.00
7/2/2025	INMB INmune Bio	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $8.00
7/1/2025	INMB INmune Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
7/1/2025	INMB INmune Bio	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Outperform ➝ Sector Underperform
6/30/2025	INMB INmune Bio	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
6/11/2025	CABA Cabaletta Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$25.00
5/19/2025	ASRT Assertio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$3.50 ➝ $3.50

(Data available from 8/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASRT Assertio	$124.96M	0.63	$0.05 per share	16.56	$0.97 per share	0.84
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	$1.95 per share	N/A
EQ Equillium	$30.41M	1.34	N/A	N/A	$0.54 per share	2.11
INMB INmune Bio	$50K	1,345.20	N/A	N/A	$1.09 per share	2.32

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASRT Assertio	-$21.58M	-$0.45	N/A	27.10	N/A	-36.97%	-38.19%	-15.45%	N/A
CABA Cabaletta Bio	-$115.86M	-$2.71	N/A	N/A	N/A	N/A	-92.11%	-74.08%	N/A
EQ Equillium	-$8.07M	-$0.56	N/A	N/A	N/A	-19.62%	-114.69%	-78.89%	N/A
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)

Latest EQ, ASRT, CABA, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	EQ Equillium	-$0.14	-$0.16	-$0.02	-$0.16	N/A	N/A
8/11/2025	Q2 2025	ASRT Assertio	-$0.10	-$0.17	-$0.07	-$0.17	$27.86 million	$29.22 million
8/7/2025	Q2 2025	CABA Cabaletta Bio	-$0.71	-$0.73	-$0.02	-$0.73	$4.17 million	N/A
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A
5/21/2025	Q1 2025	CABA Cabaletta Bio	-$0.67	-$0.71	-$0.04	-$0.71	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASRT Assertio	N/A	N/A	N/A	N/A	N/A
CABA Cabaletta Bio	N/A	N/A	N/A	N/A	N/A
EQ Equillium	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASRT Assertio	0.42	1.59	1.35
CABA Cabaletta Bio	N/A	4.78	3.96
EQ Equillium	N/A	2.70	2.70
INMB INmune Bio	N/A	4.20	2.64

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASRT Assertio	48.96%
CABA Cabaletta Bio	N/A
EQ Equillium	27.05%
INMB INmune Bio	12.72%

Insider Ownership

Company	Insider Ownership
ASRT Assertio	4.00%
CABA Cabaletta Bio	11.25%
EQ Equillium	31.60%
INMB INmune Bio	35.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASRT Assertio	20	96.24 million	92.39 million	Optionable
CABA Cabaletta Bio	50	91.47 million	81.18 million	Optionable
EQ Equillium	40	35.72 million	24.43 million	Not Optionable
INMB INmune Bio	10	26.59 million	17.09 million	Optionable

EQ, ASRT, CABA, and INMB Headlines

Recent News About These Companies

INmune Bio Inc. Stock Grades | INMB | Barron's

August 16 at 10:02 AM | barrons.com

INmune Bio, Inc. (NASDAQ:INMB) Q2 2025 Earnings Call Transcript

August 12, 2025 | msn.com

BTIG Reaffirms Their Hold Rating on Inmune Bio (INMB)

August 10, 2025 | theglobeandmail.com

Is INmune Bio (NASDAQ:INMB) In A Good Position To Deliver On Growth Plans?

August 10, 2025 | finance.yahoo.com

Inmune Bio (INMB) was downgraded to a Sell Rating at Scotiabank

August 9, 2025 | theglobeandmail.com

Inmune Bio’s Phase 2 Trial Shows Promise in Alzheimer’s

August 9, 2025 | theglobeandmail.com

INmune Bio (INMB) Q2 Loss Widens 110%

August 8, 2025 | aol.comA

INmune Bio, Inc. (INMB) Q2 2025 Earnings Call Transcript

August 8, 2025 | seekingalpha.com

INmune Bio stock soars after prostate cancer trial meets endpoints

August 4, 2025 | investing.com

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 4, 2025 | finance.yahoo.com

INmune Bio Shares Surge as Prostate Cancer Trial Achieves Key Goals

August 4, 2025 | msn.com

INmune Bio's CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment

August 4, 2025 | globenewswire.com

INmune Bio (NASDAQ:INMB) Cut to Sell at Wall Street Zen

August 3, 2025 | marketbeat.com

INmune Bio options imply 14.9% move in share price post-earnings

August 1, 2025 | msn.com

INmune Bio Inc. to Report Second Quarter 2025 Financial Results and Provide Corporate Update on Thursday, August 7th

July 31, 2025 | globenewswire.com

INmune Bio (INMB) to Release Quarterly Earnings on Thursday

July 31, 2025 | marketbeat.com

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer's Association International Conference

July 29, 2025 | globenewswire.com

2BNS, INMB : INmune Bio Rebounds Sharply During After Hours Trading: What&...

July 28, 2025 | benzinga.com

INmune Bio, Inc. (NASDAQ:INMB) Given Average Recommendation of "Moderate Buy" by Brokerages

July 26, 2025 | marketbeat.com

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference

July 25, 2025 | manilatimes.netM

INmune Bio: Thinking Through XPro's MINDFuL Data In Early Alzheimer's

July 4, 2025 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

EQ, ASRT, CABA, and INMB Company Descriptions

Assertio NASDAQ:ASRT

$0.81 -0.01 (-0.64%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$0.82 +0.00 (+0.23%)

As of 08/15/2025 07:05 PM Eastern

Assertio Holdings, Inc., a commercial pharmaceutical company, provides various products to patients in the United States. Its pharmaceutical products include INDOCIN, an oral and suppository solution for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides Sympazan, a benzodiazepine for the adjunctive treatment of seizures related with lennox-gastaut syndrome in patients aged two years of age or older; CAMBIA, a non steroidal anti inflammatory drug (NSAID) for the treatment of migraine pain, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate pain in adults; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat patients with severe, active rheumatoid arthritis, and active polyarticular juvenile idiopathic arthritis, as well as treat adult with severe, recalcitrant, and disabling psoriasis; and ROLVEDON, a long-acting granulocyte colony-stimulating factor that is indicated to decrease the incidence of infection caused by febrile neutropenia. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 2020 and is headquartered in Lake Forest, Illinois.

Cabaletta Bio NASDAQ:CABA

$1.71 +0.06 (+3.64%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.70 -0.01 (-0.58%)

As of 08/15/2025 07:52 PM Eastern

Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company's lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis. It has a collaboration with the University of Pennsylvania and the Children's Hospital of Philadelphia; Nanjing IASO Biotherapeutics Co., Ltd; Oxford Biomedica; and WuXi Advanced Therapies, Inc. The company was formerly known as Tycho Therapeutics, Inc. and changed its name to Cabaletta Bio, Inc. in August 2018. Cabaletta Bio, Inc. was incorporated in 2017 and is headquartered in Philadelphia, Pennsylvania.

Equillium NASDAQ:EQ

$1.14 +0.16 (+16.31%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$1.14 0.00 (-0.09%)

As of 08/15/2025 07:59 PM Eastern

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications. In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area. The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017. Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

INmune Bio NASDAQ:INMB

$2.53 +0.08 (+3.27%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.48 -0.05 (-1.94%)

As of 08/15/2025 07:56 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time